HIV Research for Prevention 2016:
AIDS Vaccine, Microbicide and ARV-based Prevention Science

Conference Report
Elizabeth Bukusi chairing a plenary session

Bonnie Mathieson farewell reception

Discussions during the poster session

Ambassador Deborah Birx at closing plenary

Noel Gordon, addressing a plenary

Networking Lunch

Conference photographs by Khaliq Thomas
Keynote address by Dr. Anthony Fauci

Attendees representing their research lab

Mitchell Warren with journalist fellows

Gabriella Scarlatti, at Rapporteur Session

Discussion at the media center

Participants lined up to ask questions

Conference photographs by Khaliq Thomas
Table of Contents

Introduction .................................................................................................................................................... 5

The Philosophy of HIVR4P .................................................................................................................. 5
Conference Organization ...................................................................................................................... 5
The Global Impact of HIVR4P ........................................................................................................... 5

Participant Demographics and Feedback .......................................................................................... 6

Scientific Program .................................................................................................................................. 8

Abstracts .................................................................................................................................................... 9
Satellites .................................................................................................................................................. 9

Scholarship Program ............................................................................................................................ 10

Awards ....................................................................................................................................................... 10

Desmond Tutu Award for HIV Prevention Research and Human Rights ............................................. 10
The Omololu Falobi Award for Excellence in HIV Prevention Research Community Advocacy .......... 11
Mathieson Award to a New Investigator in HIV Research .................................................................... 11

Media Program ........................................................................................................................................ 11

Partnership Program .............................................................................................................................. 12

Appendix ................................................................................................................................................ 13

Committees ........................................................................................................................................... 13
New Investigator Awardees .................................................................................................................. 18
Conference Scholars ............................................................................................................................... 18
Introduction

The Philosophy of HIVR4P

HIV Research for Prevention 2016: AIDS Vaccine, Microbicide and ARV-based Prevention Science (HIVR4P) was held at the Sheraton Grand Chicago in Chicago, Illinois, United States, 17-21 October 2016. The biennial HIVR4P conference is the only global scientific meeting dedicated exclusively to biomedical HIV prevention research, including HIV vaccines, microbicides, PrEP, treatment as prevention and other biomedical prevention approaches.

“Partnering for Prevention” was the theme of HIVR4P 2016, as well as the philosophy that guided the entire conference. Unlike previous gatherings that focused on a single form of prevention, such as vaccines or microbicides, HIVR4P built on a growing consensus that effective HIV prevention requires combination approaches, and that understanding, analyzing and debating the cross-cutting issues that impact prevention research are key to reducing the global epidemic. “Partnering for Prevention” represented the conference’s commitment to breaking down silos between research disciplines, and between researchers, program developers, care providers, advocates, communities and funders.

HIVR4P supports cross-fertilization between different biomedical prevention approaches and provides a venue to discuss the research findings, questions and priorities specific to each modality, and to global HIV prevention efforts as a whole. Consistent with this philosophy, the conference program for HIVR4P 2016 included every major facet of a rapidly evolving biomedical HIV prevention paradigm.

Conference Organization

Planning for HIVR4P was led by an international panel of conference co-chairs comprised of:

- Thomas Hope, Northwestern University, United States
- Jeanne Marrazzo, University of Alabama at Birmingham, United States
- Lynn Morris, National Institute for Communicable Diseases and University of Witwatersrand, South Africa
- Nelly Mugo, Kenya Medical Research Institute, Kenya

In addition, the conference organization included a diverse, multi-disciplinary 45-member Program Organizing Committee (POC), made up of leading researchers, policymakers and advocates from around the world, as well as 68 additional experts who comprised the Abstract Review Committee that reviewed 934 abstract submissions to develop the 32 oral and poster discussion sessions that drove the HIVR4P program (See appendix for committee members). The Global HIV Vaccine Enterprise served as secretariat for HIVR4P.

HIVR4P attracted a broad array of financial and in-kind supporters, including governmental agencies, leading foundations, research institutions, universities, advocacy organizations and pharmaceutical companies.

The Global Impact of HIVR4P

To extend the global reach of the conference and to continue the discussions begun at HIVR4P, research presented at the conference was made available through a variety of platforms. These outreach efforts included:
• Webcasting conference sessions within 24 hours of presentation on HIVR4P website, making the conference accessible world-wide, free of charge (http://webcasts.hivr4p.org/). In HIVR4P 2016, audio of all oral presentations was posted on the conference website. This arrangement was introduced keeping in mind the concurrent sessions at the conference that often prevented delegates from attending all talks of interest.

• Highlighting take-home messages from the conference through presentations at the newly introduced Rapporteur Session and through Daily Rapporteur Summary Reports posted on the conference website (http://hivr4p.org/program/rapporteur-summaries).

• Extensive media coverage for the conference generated through a robust journalist training program and media outreach leading to 109 unique regional and international media reports (See Media Program section).

• Publication of all conference abstracts in an open access supplement of AIDS Research and Human Retroviruses (http://online.liebertpub.com/toc/aid/32/S1).

• Providing a user-friendly, open access electronic archive of posters (ePosters), hosting nearly half of the posters presented at HIVR4P (http://www.abstractstosubmit.com/hivr4p2016/eposter/).

• Making presentation details available to conference attendees and those following the proceedings from afar through a newly designed online planner and mobile app, which allowed users to browse the conference agenda, search sessions and abstracts by keyword and create a personalized conference schedule (http://www.professionalabstracts.com/hivr4p2016/iPlanner/#/grid).

Interest in HIVR4P remained high even after the last day: in the three weeks following the conference the webcasting page received 15,138 page views by 2,556 unique users. Additionally, the ePosters received 1090 page views in two weeks post-conference. Since publication of the ARHR supplement abstracts were downloaded 973 times. The mobile app received 42,839 page views by 706 users, representing approximately 50% of conference attendees.

News from the conference was also communicated to a global audience through the HIVR4P Facebook page, and a very active Twitter feed #HIVR4P2016.

Participant Demographics and Feedback

Attendance at HIVR4P 2016 met or exceeded all organizational targets. In all, 1,419 delegates from 42 countries participated in the meeting. North America and Africa were the continents represented the most (82%). HIVR4P 2016 attracted a higher proportion of U.S.-based attendees than the first HIVR4P conference, which was held in Cape Town, South Africa. In all, 64.4% of attendees at the 2016 meeting came from North America. More than one in six attendees (17.5%) were from Africa; 11.7% of attendees were from Europe and 4% of came from Asia. A majority of African delegates were from South Africa (88 attendees), Kenya (52 attendees), Uganda (31 attendees) and Nigeria (27 attendees). England (55 attendees) and France (45 attendees) sent the most delegates from Europe. India, China and Thailand (17, 14 and 13 delegates, respectively) were the most represented Asian countries at the conference.
Over a third of HIVR4P attendees (>568) were Junior and Early Career Investigators (JECIs) from around the world. Non-paid registrations included conference scholarship recipients (247), media attendees (46) including 23 journalist fellows, invited speakers (66) and staff, hosts, committee members, additional complimentary attendees and sponsors (55).

The strong scientific program at HIVR4P was reflected in the professional focus of the attendees, 74% of whom described their primary focus as research. Policymakers, advocates, funders, educators and media representatives made up the remaining conference attendees.

A key objective of HIVR4P is to provide a platform for the latest development in every major field of biomedical HIV prevention. A review of the primary field of HIV prevention work of conference attendees indicates that the objective was met, with nearly equal representation among the attendees of individuals who said that the primary focus of their work was vaccines (19%), clinical research (15%), PrEP (14%), basic science (13%), public health (13%) and microbicides (12%). Smaller proportions of attendees listed their primary focus as social science (6%) and treatment as prevention (4%).
The overwhelming majority of survey respondents who attended HIVR4P (more than 97%) said they were satisfied with the conference, with 90% indicating that they were either highly satisfied (51%) or satisfied with minor reservations (39%). When asked to choose which aspect of the conference they liked most, respondents cited the quality of presentations and diversity of topics and speakers (67%); the fact that the conference combined multiple prevention research modalities (52%); the organization of the meeting (45%); and the opportunity that HIVR4P provided for young researchers and African scientists to engage, participate in and contribute to the conference (41%). Areas for improvement included food/networking opportunities provided (49%) and scheduling of parallel sessions (26%).

The vast majority of survey respondents either agreed or strongly agreed that the conference format allowed for topic focus while also promoting interchange between disciplines (91%); that the concerns and contributions of different constituencies were well represented in the program (82%); that HIVR4P fostered a dialogue between participants from different fields (91%); and that the participation of African researchers and community members was visible throughout the program (84%).

**Scientific Program**

HIVR4P included the presentation of more than 181 research studies in 24 oral abstract and eight poster discussion sessions; four plenary sessions; 12 symposia and roundtables; and 21 satellite sessions organized by research organizations, community-based organizations, advocates and other experts from around the world (http://hivr4p.org/program/satellite-sessions).

Two new programs were introduced at HIVR4P 2016. Meet the Experts sessions provided the opportunity for dialogue with plenary speakers thus expanding learning opportunities for attendees and allowing for in-depth discussion of critical topics. The Rapporteur Session, with talks from four rapporteur leads (who were assisted by 11 rapporteurs), summarized key research breakthroughs presented at the conference across topic areas. This overview session on the last day was planned keeping in mind HIVR4P’s program with 36 concurrent sessions that at times prevented delegates from attending all talks of interest.

Topics on the HIVR4P agenda addressed cross-cutting issues that impact multiple HIV prevention modalities as well as questions specific to particular interventions. Some of the conference program topics were:

- HIV transmission dynamics and lessons for implementing HIV prevention strategies
- Advances in mucosal immunology with emphasis on intervention opportunities
- PrEP provision and roll-out in different countries and populations around the world
- Follow-up on dapivirine ring clinical trials; recent progress in topical prevention science and multi-purpose prevention technologies
- Updates on recent and upcoming clinical trials testing different intervention approaches such as vaccine candidates, long-acting ARVs etc.
- Passive immunization with broadly neutralizing antibodies including AMP clinical trial updates
- Antibody epitopes and immunogenicity of the Envelope protein
- Acquisition risk in vulnerable populations including adolescents and ways to target interventions
- Frameworks for implementation including lessons learnt from social science research
- Behavioral and adherence challenges in implementing prevention approaches
- Community engagement and advocacy in prevention research

Among the topics generating the most media coverage at HIVR4P were:
• PrEP efficacy, use and obstacles to access
• Follow-on learnings from the dapivirine ring studies, including the impact of stigma on ring use
• SIV control in Macaques treated with a4b7
• The prevention impact of increased services for key populations, including MSM and sex workers
• Advances in vaccine science and the impending start of the HVTN702 study
• Advances in long-acting prevention

Abstracts

HIVR4P 2016 received 812 complete abstract submissions during the standard submission period and 122 additional late breaker abstracts. All submitted abstracts were assigned to five to seven independent reviewers for evaluation and reviewed by a minimum of three. A total of 115 individuals with expertise in the relevant scientific program areas assisted in the abstract review process. Of the 934 abstract submissions received, 768 abstracts were accepted and scheduled for presentation at the conference.

• 136 standard and eight late breaker abstracts were selected for oral presentation in 24 oral abstract sessions
• 575 posters were scheduled for presentation, 37 of which were selected for a 9-minute oral poster presentation
• 49 submissions were originally accepted for presentation but later withdrawn by the authors
• 166 abstracts were rejected

Abstracts were submitted in 28 different topic areas, many of which highlighted the cross-disciplinary nature of the conference. As with participants’ interest in HIV prevention research, abstracts presented were distributed relatively evenly amongst the different topics. The ten abstract topics with the most presented abstracts are shown below and represents multiple prevention modalities and cross-cutting issues.

Satellites

HIVR4P hosted 21 satellite sessions in advance of and immediately following the official conference proceedings. Selected to complement the conference programs, satellite sessions were planned by research organizations, community-based organizations, advocates and other experts from around the world. Satellite sessions covered diverse topics including systemic and topical delivery of anti-HIV monoclonal antibodies, multipurpose
prevention technologies, an advocates pre-conference workshop, showcasing African-led basic HIV prevention research, non-human primate models for HIV prevention and many others. More details on the satellite session program are available at [http://hivr4p.org/program/satellite-sessions](http://hivr4p.org/program/satellite-sessions).

More than 95% of survey respondents who attended HIVR4P satellite sessions said that those events were well-organized, addressed important issues and added to the conference program and to the respondents’ conference experience.

**Scholarship Program**

HIVR4P provided a limited number of competitive scholarships, designed to enable the participation of researchers and students who may not otherwise have been able to attend the meeting. To be considered for a scholarship, applicants submitted a statement describing their career interests, reasons for wanting to attend the conference and need for financial assistance. The program organizing committee reviewed all applications by merit and gave preference to applicants who presented work at the conference and had no funds to participate otherwise. A total of 501 scholarship applications were received in two categories: research (342) and community (159). **196 full conference scholarships, 8 new investigator awards and 60 complimentary registrations were awarded to successful applicants.** Researchers and community members from Africa received 113 full and 15 registration-only scholarships; 32 full and 33 registration-only scholarships were awarded to participants from North America; 29 full and 5 registration-only scholarships went to European applicants; 17 full and 7 registration-only scholarships went to applicants from Asia and Australia; and South American research and community members were awarded 5 full scholarships (See appendix or [http://hivr4p.org/scholarships/2016-scholars](http://hivr4p.org/scholarships/2016-scholars) for full list of scholars).

**Awards**

**Desmond Tutu Award for HIV Prevention Research and Human Rights**

At the closing plenary, the Desmond Tutu Award for HIV Prevention Research and Human Rights was presented to Ambassador Deborah Birx, U.S Global AIDS Coordinator and director of the PEPFAR program. This recognition, given by HIVR4P every two years to an individual or organization that has done outstanding work to advance HIV prevention research and human rights, was first presented to Archbishop Tutu in 2014 in Cape Town.

The Desmond Tutu Award highlights a central tenet of the HIVR4P philosophy: that human rights and HIV prevention are inextricably linked; that respect for the human rights of people affected by HIV is essential to slowing the epidemic; and that all people impacted by this epidemic have a central role to play in creating an AIDS-free future. Presenting the award to Ambassador Birx, HIVR4P Co-chair Nelly Mugo said, “Long before the term “key populations” gained currency, Ambassador Birx’s leadership across more than thirty years of HIV research, care and advocacy focused on the dignity of every individual affected by HIV, the challenges posed by stigma and lack of opportunity, and the capacity of empowered individuals to care for themselves and others. She has never taken her eyes off the human face of the epidemic.”
The Omololu Falobi Award for Excellence in HIV Prevention Research Community Advocacy

Named in honor of activist, prevention research advocate and journalist Omololu Falobi, this biennial award honors individuals who have shown leadership in and commitment to HIV prevention research advocacy and inspired others to action. At the HIVR4P Closing Plenary, Manju Chatani of AVAC presented the award to all nominated advocates, researchers, policymakers, journalists, funders and research volunteers who have taken the field of HIV prevention research so far forward since Omolulu Falobi’s death and the establishment of the award in 2006. An inspiring photo collage of the 85 recipients of the 2016 award showed the diversity of community advocates who are advancing HIV prevention research worldwide. The cash prize was given to Omololu’s three children to help support their education.

Mathieson Award to a New Investigator in HIV Research

The Mathieson Award was presented for the first time at HIVR4P 2016. The award honors Bonnie Mathieson for her contributions to the HIV research field, and particularly for her passion and dedication in mentoring young investigators in her former role as HIV vaccines lead at the NIH Office of AIDS Research. In recognition of Mathieson’s long-standing belief that some of the most innovative prevention research can be found “in the posters,” the first Mathieson Award to a New Investigator was presented as part of the Wednesday poster session at HIVR4P. The recipient of the inaugural Mathieson Award was Cassandra Simonich, an MD/PhD student from Fred Hutchinson Cancer Research Center.

Media Program

Forty-six journalists from 18 countries attended and reported on HIVR4P. To facilitate the accurate communication of research news from the conference to a global media audience, the HIVR4P media program included:

- A fully operational media center, open throughout the conference
- Daily press conferences and pre-plenary briefings for journalists, and additional meet-the-expert sessions to facilitate accurate coverage of emerging issues and research stories
- Ongoing support in obtaining expert interviews and story development

Topics for HIVR4P press conferences included Highlights in Research on Vaccines and Early Infection; PrEP Roll-Out, Use and Challenges; New and Emerging Prevention Approaches, including Long-Acting Prevention; and Access to Prevention. As of December 1, 2016, 109 unique media reports on research presented at HIVR4P had been collected from media outlets around the world.

HIVR4P also offered a Journalist Fellowship program for highly qualified media representatives with an extensive track record of covering HIV prevention research, whose media outlets would otherwise not be able to send them to the conference. Begun at the AIDS Vaccine 2009 conference, HIVR4P 2016 represented the seventh iteration of this Journalist Fellowship program, which has become a model for other conferences seeking to increase accurate, high-profile media coverage of their work. The Journalist Fellowship program includes a 1.5
day training program on the latest developments in HIV prevention research, facilitated by leading researchers in the field.

The conference received 198 applications for HIVR4P 2016 Journalist Fellowships from reporters in 54 countries. Twenty-three fellows were selected to participate in the program, representing media outlets in Brazil, China, Cuba, France, India, Kenya, Malawi, Nigeria, South Africa, Uganda, United Kingdom, United States, Vietnam, Zambia and Zimbabwe.

**Partnership Program**

The success of the HIVR4P 2016 conference is due in large part to the generosity of our funding partners. Their contributions keep registration affordable, ensure that the conference is accessible to individuals from across the globe, and make conference scholarships possible.

**2016 Funding Partners**

ANRS  
Bill & Melinda Gates Foundation  
Centre for the AIDS Programme of Research in South Africa (CAPRISA)  
Gilead  
GSK Biologicals  
International AIDS Vaccine Initiative (IAVI)  
International Partnership for Microbicides (IPM)  
Janssen Pharmaceuticals

National Institutes of Health (NIH)  
Population Council  
Sanofi Pasteur  
South African Medical Research Council (MRC)  
The United States President’s Emergency Plan for AIDS Relief (PEPFAR)  
United States Agency for International Development (USAID)  
ViiV Healthcare
Appendix

Committees

Conference Chairs

Thomas Hope
Northwestern University, United States

Jeanne Marrazzo
University of Alabama at Birmingham School of Medicine, United States

Lynn Morris
National Institute for Communicable Diseases and University of the Witwatersrand, South Africa

Nelly Mugo
Kenya Medical Research Institute, Kenya

Conference Secretariat

Global HIV Vaccine Enterprise, United States

Kristin Morrell
Funders Relations Officer

Bargavi Thyagarajan
Science Officer

Gabriella Scarlatti
Science Director

Mark Aurigemma
Media Consultant

Program Organizing Committee

Marcus Altfeld
Heinrich Pette Institute, Leibniz-Institute for Experimental Virology, Germany

Jintanat Ananworanich
U.S. Military HIV Research Program, United States

Susann B. Buchbinder
San Francisco Department of Public Health, United States

Elizabeth Bukusi
Kenya Medical Research Institute, Kenya

Dan Barouch
Beth Israel Deaconess Medical Center, Ragon Institute of MGH, MIT and Harvard, United States

Kundai Chinyenze
International AIDS Vaccine Initiative, Kenya

Gina Brown
Office of AIDS Research, National Institutes of Health, United States

Z. Mike Chirenje
University of Zimbabwe-University of California San Francisco Collaborative Research Program, Zimbabwe
Myron Cohen
University of North Carolina, United States

David Cooper
Kirby Institute, University of New South Wales, Australia

Carl Dieffenbach
National Institute of Allergy and Infectious Diseases, NIH, United States

Mark Feinberg
International AIDS Vaccine Initiative, United States

Geoff Garnett
Bill & Melinda Gates Foundation, United States

Barney Graham
Vaccine Research Center, NIAID, NIH, United States

Beatriz Grinsztejn
Oswaldo Cruz Foundation, Brazil

Scott Hammer
Columbia University, United States

Catherine Hankins
Amsterdam Institute for Global Health and Development, Netherlands

Barton Haynes
Duke University, United States

Sharon Hillier
University of Pittsburgh School of Medicine, United States

Eric Hunter
Emory University and Emory Vaccine Center, United States

Anatoli Kamali
International AIDS Vaccine Initiative, Kenya

Angela Kashuba
University of North Carolina, United States

Milly Katana
MTN Community Working Group/Senior Support Services, Uganda

Wayne Koff
Human Vaccines Project, United States

Raphael Landovitz
UCLA Center for Clinical AIDS Research and Education, United States

Jean-Daniel Lelièvre
INSERM/VRI (University Paris-Est Créteil), France

Bonnie Mathieson
Office of AIDS Research, NIH, United States

Ken Mayer
The Fenway Institute, Beth Israel Deaconess Medical Center, Harvard Medical School, United States

Sheena McCormack
Medical Research Council Clinical Trials Unit at University College London, United Kingdom

Lyle McKinnon
University of Manitoba/Centre for the AIDS Programme of Research in South Africa (CAPRISA), Canada and South Africa

Andrew Mujugira
Department of Global Health, University of Washington, Uganda
Thumbi Ndung’u
University of KwaZulu-Natal, South Africa

Jim Pickett
International Rectal Microbicide Advocates, United States

Gita Ramjee
HIV Prevention Research Unit, South African Medical Research Council, South Africa

Helen Rees
RHI: Wits Reproductive Health and HIV Institute, South Africa

Nina Russell
Bill & Melinda Gates Foundation, United States

William Schief
Scripps Research Institute and International AIDS Vaccine Initiative, United States

Barbara Shacklett
University of California, Davis, United States

Yiming Shao
National Center for AIDS/STD Control and Prevention (NCAIDS), and Chinese Center for Disease Control and Prevention, China

Robin Shattock
Imperial College London, United Kingdom

William Snow
Global HIV Vaccine Enterprise, United States

Morenike Ugboola
Obafemi Awolowo University, Nigeria

Mitchell Warren
AVAC, United States

Kim Woodrow
University of Washington, United States

Ntando Yola
Desmond Tutu HIV Foundation, South Africa

Abstract Reviewers

In addition to the Program Organizing Committee, the following individuals reviewed abstracts

Alash’le Abimiku
Institute of Human Virology Nigeria, Nigeria

Todd Allen
Harvard University, United States

Galit Alter
Ragon Institute of MGH, MIT and Harvard University, United States

Rama Amara
Emory University, United States

Jared Baeten
University of Washington, United States

Prince Bahati
International AIDS Vaccine Initiative, Kenya

Christian Brander
IrsiCaixa, Spain

Nomita Chandhiok
Indian Council of Medical Research, India
Robert Chen  
Centers for Disease Control and Prevention, United States  

Josephine Cox  
International AIDS Vaccine Initiative, United States  

Cynthia Derdeyn  
Emory University, United States  

Gustavo Doncel  
Eastern Virginia Medical School, United States  

Daniel Douek  
Vaccine Research Center, NIAID, NIH, United States  

Patricia Fast  
International AIDS Vaccine Initiative, United States  

Kevin Fisher  
AVAC, United States  

Keith Fowke  
University of Manitoba, Canada  

Nicole Frahm  
Fred Hutchinson Cancer Research Center, United States  

Henry Gabelnick  
Eastern Virginia Medical School Emeritus, United States  

J. Victor Garcia  
University of North Carolina at Chapel Hill, United States  

Paul Goepfert  
University of Alabama at Birmingham, United States  

Tomas Hanke  
University of Oxford, United Kingdom  

Craig Hendrix  
Johns Hopkins University, United States  

Walid Heneine  
Centers for Disease Control and Prevention, United States  

Betsy Herold  
Albert Einstein College of Medicine/Montefiore Medical Center, United States  

Stephen Kent  
University of Melbourne, Australia  

Jerome Kim  
International Vaccine Institute, Korea  

Charles Lacey  
University of York, United Kingdom  

Roger Le Grand  
CEA, France  

Yves Lévy  
INSERM/VRI, France  

George Lewis  
Institute of Human Virology, United States  

Amapola Manrique  
Global HIV Vaccine Enterprise, United States  

John Mascola  
Vaccine Research Center, NIAID, NIH, United States  

Benoît Masse  
University of Montreal, Canada  

Barbara Mensch  
Population Council, United States  

Nelson Michael  
U.S. Military HIV Research Program, United States  

Penny Moore  
University of the Witwatersrand, South Africa
Jeremy Nuttall
International Partnership for Microbicides, United States

Jean Patterson
Office of AIDS Research, United States

Dorothy Patton
University of Washington, United States

Punnee Pitisuttithum
Vaccine Trial Centre, Faculty of Tropical Medicine, Mahidol University, Thailand

Damian Purcell
University of Melbourne, Australia

Merlin Robb
U.S. Military HIV Research Program, United States

Harriet Robinson
GeoVax Inc., United States

Lisa Rohan
University of Pittsburgh, United States

Morgane Rolland
U.S. Military HIV Research Program, Henry M. Jackson Foundation for the Advancement of Military Medicine, United States

Joseph Romano
NWJ Group, United States

Ruth Ruprecht
Texas Biomed, United States

Jeffrey Safrit
International AIDS Vaccine Initiative, United States

Eric Sandström
Karolinska Institutet, Sweden

Gabriella Scarlatti
Global HIV Vaccine Enterprise, United States

Alexandra Schuetz
U.S. Army Medical Component of the Armed Forces Research Institute of the Medical Sciences, Thailand

Olivier Schwartz
Institut Pasteur, France

Guido Silvestri
Emory University, United States

Jonathan Stadler
University of Witwatersrand, South Africa

Alan Stone
MEDSA Ltd, United Kingdom

Hendrik Streeck
Institute for HIV Research, Germany

Jim Tartaglia
Sanofi Pasteur, United States

Bargavi Thyagarajan
Global HIV Vaccine Enterprise, United States

Caroline Tiemessen
National Institute for Communicable Diseases, South Africa

Georgia Tomaras
Duke Human Vaccine Institute, United States

Alexandra Trkola
University of Zurich, Switzerland

Jim Turpin
Prevention Sciences Program, DAIDS, NIAID, NIH, United States

Lut Van Damme
Bill & Melinda Gates Foundation, United States

Ronald Veazey
Tulane National Primate Research Center, United States
Steven Wakefield  
HIV Vaccine Trials Network, United States

Anna-Lise Williamson  
University of Cape Town, South Africa

**New Investigator Awardees**

Yoann Aldon  
Imperial College London, United Kingdom

Smritee Dabee  
Institute of Infectious Disease and Molecular Medicine, University of Cape Town, South Africa

Elina El-Badry  
Emory University, United States

Kenneth Mugwanya  
University of Washington, United States

Daniel Sheward  
University of Cape Town, South Africa

**Conference Scholars**

Isaac Adejo  
Achieving Health Nigeria Initiative, Nigeria

Oladele Adeniyi  
Walter Sisulu University/East London Hospital Complex, South Africa

Adedayo Adeyemi  
Healthmatch International, Nigeria

Gabriel Adeyemo  
Texila American University School of Public Health, University of Central Nicaragua, Guyana

Allen Zhiwei Wu  
Nanjing University Medical School, China

Susan Zolla-Pazner  
Icahn School of Medicine at Mount Sinai, United States

Devin Sok  
International AIDS Vaccine Initiative (IAVI), United States

Ekaterina Taneva  
Albert Einstein College of Medicine/Montefiore Medical Center, United States

Marit van Gils  
Academic Medical Center, University of Amsterdam, Netherlands

Collins Agaba  
The AIDS Support Organisation (TASO), Uganda

Heena Aggarwal  
All India Institute of Medical Sciences, India

Wbeimar Aguilar-Jimenez  
Grupo Inmunovirología, Universidad de Antioquia, Colombia

Shubbir Ahmed  
Translational Health Science and Technology Institute (THSTI), India
Carolyne Akello
MU-JHU Research Collaboration, Uganda

Toyese Akinade
Population Council, Nigeria

Maureen Akolo
University of Manitoba/University of Nairobi-Kenya
AIDS Control Project, Kenya

Obiajulu Augustina Amuamuziam
New HIV Vaccine and Microbicides Advocacy
Society (NHVMAS), Nigeria

Neeti Ananthaswamy
The Catholic University of America, United States

Joseph Anejo-okopi
University of Jos, Nigeria

Colin Anthony
University of Cape Town, South Africa

Kanchana Ayyar
National Institute for Research in Reproductive
Health, India

Ubaldo Bahemuka
Medical Research Council/Uganda Virus Research
Institute (UVRI), Uganda

Gabriela Baldeon Vaca
Boston University School of Medicine, United States

Andrew Banin
New York University Langone Medical Center,
United States

Shaun Barnabas
University of Cape Town, South Africa

Anna-Janina Behrens
University of Oxford, United Kingdom

Anna Blakney
University of Washington, United States

Melanie Bouvin-Pley
INSERM U966, France

Charles Brown
Infectious Diseases Institute, Uganda

William Brown III
HIV Center for Clinical and Behavioral Studies,
Columbia University, United States

Sarah Calabrese
Yale School of Public Health, United States

Ann Carias
Northwestern University, United States

Mariangela Cavarelli
Commissariat à L’énergie Atomique et aux Énergies
Alternatives (CEA), France

Kingsley Chasanga
Malawi Network of AIDS Service Organisations
(MANASO), Malawi

Narayanaiah Cheedarla
National Institute for Research in Tuberculosis, India

Deyan Chen
Nanjing University, China

Jian Chen
Shanghai Public Health Clinical Center, Fudan
University, China

Ryan Cheu
University of Washington, United States
Stanford Chimutimunzeve  
University of Zimbabwe-University of California San Francisco School of Medicine, Zimbabwe

Jonah Chinga  
Gay and Lesbian Coalition of Kenya, Kenya

Daniel Claiborne  
Ragon Institute of MGH, MIT and Harvard, United States

Uchenna Clifford Ononaku  
International Center for Advocacy on Rights to Health/Institute of Human Virology Nigeria, Nigeria

Núria Climent  
Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Spain

Supratik Das  
Translational Health Science and Technology Institute (THSTI), India

José das Neves  
i3S – Instituto de Investigação e Inovação em Saúde, University of Porto, Portugal

Suprit Deshpande  
Translational Health Science and Technology Institute (THSTI), India

Zanele Ditse  
National Institute for Communicable Diseases of the National Health Laboratory Service, South Africa

Sara Dizzell  
McMaster University, Canada

Sigcinile Dlamini  
University of Cape Town, South Africa

Bisheng Dong  
Nanjing University, China

Clare Dott  
Wits Reproductive Health and HIV Institute, South Africa

Camille Ducloy  
INSERM U1109, FMTS Université de Strasbourg, France

Florita Durueke  
New HIV Vaccine and Microbicides Advocacy Society, Nigeria

Godfrey Dzhivhuho  
University of Cape Town, South Africa

Hanna Ebner  
Institute of Medical Virology, University of Zurich, Switzerland

James Eghaghe  
Equal Health and Rights Access Advocacy Initiative, Nigeria

Amaka Enemo  
Nigeria Sex Workers Association, Nigeria

René Ghislain Essomba  
Faculty of Medicine and Biomedical Sciences, University of Yaoundé, Cameroon

Juliane Etima  
MU-JHU Research Collaboration, Uganda

Olubunmi Fakunle  
Public Health Department, Nigeria

Teresa Filipowicz  
Rwanda Zambia HIV Research Group, Zambia
Anna Forbes
Self-Employed, United States

Joseph Francica
National Institutes of Health, United States

Johannes Gach
University of California Irvine, United States

Maria Lucia Gallo Vaulet
Universidad de Buenos Aires, Facultad de Farmacia y Bioquimica, Argentina

Hoyam Gamieldien
University of Cape Town, South Africa

Lucy Ghati
KELIN, Kenya

Anna Gibbs
Karolinska Institutet, Sweden

Serah Gitome
Kenya Medical Research Institute, Kenya

Christopher Gonelli
Peter Doherty Institute for Infection and Immunity, University of Melbourne, Australia

Aleksandr Gorin
David Geffen School of Medicine at University of California, Los Angeles, United States

Eliza Govender
Centre for the AIDS Programme of Research in South Africa (CAPRISA), South Africa

Marielle Goyette
University of Washington, United States

Sheila Grab
Magee-Womens Research Institute, University of Pittsburgh School of Pharmacy, United States

Anneke (Anna Christina) Grobler
Centre for the AIDS Programme of Research in South Africa (CAPRISA), South Africa

Alberto Guardo
Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Spain

Clement Haek
Queen’s University Belfast, United Kingdom

Goli Haidari
Imperial College London, United Kingdom

Lydia Hani
INSERM U955, Equipe16, France

Rushil Harryparsad
University of Cape Town, South Africa

Carolina Herrera
Imperial College London, United Kingdom

Ann Hessell
Oregon Health & Science University, United States

Jonathon Himes
Duke University, United States

Alexandra Hoagland
Projet San Francisco (PSF), Rwanda

Maria Pia Holgado
Instituto de Investigaciones Biomedicas en Retrovirus y SIDA, Argentina

Xintao Hu
National Cancer Institute at Frederick, United States
Samantha Humby  
University of Cape Town, South Africa

Marla Husnik  
Fred Hutchinson Cancer Research Center/University of Washington, United States

Chiedu Ifekandu  
Population Council, Nigeria

Alexy Inciarte  
Hospital Clinic, Spain

Andrea Introini  
Karolinska Institutet, Sweden

Elizabeth Irungu  
Partners in Health Research and Development/Jomo Kenyatta University of Agriculture and Technology, Kenya

Michelle Isaacs  
International Partnership for Microbicides (IPM), South Africa

Margaret Japhet  
Obafemi Awolowo University, Nigeria

Kunal Jhunjunwala  
University of Pittsburgh, United States

Agricola Joachim  
Muhimbili University of Health and Allied Sciences, Tanzania

Vineet Joag  
University of Toronto, Canada

Jeremiah Johnson  
Treatment Action Group, United States

Kadryn Kadasia  
Boston University, United States

Jane Karonge  
LVCT Health, Kenya

Robinson Karuga  
LVCT Health, Kenya

Chilufya Kasanda  
Treatment Advocacy and Literacy Campaign, Zambia

Sulaiman Kawooya  
AIDS Healthcare Foundation/Uganda Cares Masaka, Masaka Healthcare Centre, Masaka Regional Referral Hospital, Uganda

Barbarah Kawoozo  
Uganda Virus Research Institute (UVRI)—International AIDS Vaccine Initiative (IAVI), Uganda

Ayesha Kharsany  
Centre for the AIDS Programme of Research in South Africa (CAPRISA), South Africa

Elvis Kidzeru  
University of Cape Town, South Africa

Hannah King  
Burnet Institute, Australia

Jairus Kipyego  
Partners in Prevention–Moi University, Kenya

Michael Kiragu  
LVCT Health, Kenya

Paul Kitandwe  
Uganda Virus Research Institute (UVRI)—International AIDS Vaccine Initiative (IAVI), Uganda
Ntombikhona Maphumulo
University of KwaZulu Natal, South Africa

Emmanuel Aubrey Margolin
University of Cape Town, South Africa

Danijela Maric
Northwestern University, United States

Michelle Maritz
University of Cape Town, South Africa

Romain Marlin
Immunology of Viral Infections and Autoimmune Diseases/IDMIT
Infrastructure/CEA/DRF/iMETI/Division of Immuno-Virology, Université Paris Sud, INSERM U 1184, France

Elena Martinelli
Population Council, United States

David Martinez
Duke University, United States

Sylvia Masawi
Medical Research Council/Uganda Virus Research Institute (UVRI), Uganda

Jane Humphrey Mashingia
East African Community Secretariat, Tanzania

Chamunorwa Mashoko
International Partnership for Microbicides (IPM), Zimbabwe

Luzia Mayr
INSERM U1109, FMTS, Université de Strasbourg, France

Towela Mfune
Zambia Emory HIV Research Project, Zambia

Dieter Mielke
University of Cape Town, South Africa

Joseph Mogunde Obunga
Jaramogi Oginga Odinga Teaching and Referral Hospital, Kenya

Boitumelo Mokgatla
International AIDS Vaccine Initiative (IAVI), Botswana

Luis Manuel Molinos-Albert
AIDS Research Institute, IrsiCaixa-HIVACAT, Spain

Thandeka Moyo
University of Cape Town, South Africa

Juliet Mpando
Uganda Virus Research Institute (UVRI)—International AIDS Vaccine Initiative (IAVI), Uganda

Steven Muchnick
Bridge HIV, HVTN GCAB, UCSF/SFGH ACTU CAB, ACTG GCAB, DARE CAB, Getting to Zero SF CAB, KPSF HIV
Update Editorial Board, ATAC DDC, United States

Peter Mugo
KEMRI Wellcome Trust, Kenya

Luke Muir
Imperial College London, United Kingdom

Jeannine Mukamuyango
Projet San Francisco (PSF)/Rwanda Zambia HIV Research Group-Emory University, Rwanda

Erick Muok
Projet San Francisco (PSF), Rwanda

Marianne Mureithi
University of Nairobi, Kenya
Kennedy Mutai Kipkoech
Kenya Medical Research Institute, Centre for Global Health Research, Kenya

Gaudensia Mutua
University of Nairobi, Kenya

Timothy Muwonge
Makerere University, Uganda

Kenneth Mwehonge
Coalition for Health Promotion and Social Development (HEPS Uganda), Uganda

Lawrence Mwihaki
Partners in Health and Research Development (PHRD), Kenya

Lillian Mworeko
International Community of Women Living with HIV Eastern Africa, Uganda

Helga Naburi
Muhimbili University of Health and Allied Sciences, Tanzania

Faith Naddunga
Medical Research Council/Uganda Virus Research Institute (UVRI), Uganda

Kalendri Naidoo
Centre for the AIDS Programme of Research in South Africa (CAPRISA), South Africa

Lillian Naigaga Mutengu
International AIDS Vaccine Initiative (IAVI), Kenya

Gonasagrie Nair
Centre for the AIDS Programme of Research in South Africa (CAPRISA), South Africa

Jauhara Nanyondo
Makerere University Walter Reed Project, Uganda

Gertrude Nanyonjo
Uganda Virus Research Institute (UVRI)—International AIDS Vaccine Initiative (IAVI), Uganda

Robert Newells
AIDS Project of the East Bay, United States

Jane Ng’ang’a
KAVI-Institute of Clinical Research, Kenya

John Ng’ang’a
University of Manitoba/University of Nairobi—Kenya Aids Control Project (KACP), Kenya

Sinaye Ngcapu
Centre for the AIDS Programme of Research in South Africa (CAPRISA), South Africa

Kenneth Ngure
Jomo Kenyatta University of Agriculture and Technology, Kenya

Philip Nguyen
McMaster University, Canada

Melanie Nicol
University of Minnesota, United States

Njambi Njuguna
Partners in Health and Research Development, Kenya

Stella Njuguna
Kenya Medical Research Institute, Kenya

Veronica Noseda
Planned Parenthood, France
Supercharger Moses Nsubuga
Joint Clinical Research Centre, Uganda

Borna Achieng Nyaoke
KAVI–Institute of Clinical Research, University of Nairobi, Kenya

Delvin Nyasani
Kenya Aids Vaccine Initiative–Institute of Clinical Research, Kenya

Julien Nyombayire
Projet San Francisco (PSF)/Rwanda Zambia HIV Research Group–Emory University, Rwanda

Stephen Okoboi
The AIDS Support Organisation (TASO), Uganda

Abiola Olaleye
Achieving Health Nigeria Initiative, Nigeria

Oladipupo Olaleye
University of Ibadan, Nigeria

Kennedy Olango
Men Against AIDS Youth Group, Kenya

Adeolu Oluremi
Ladoke Akintola University of Science and Technology, Nigeria

Regina Ombam
National AIDS Control Council, Kenya

Simon Ondiek
HIV/AIDS Research & Advocacy Programme, Kenya

Chiara Orlandi
Human Virology Institute, University of Maryland, United States

Sophia Osawe
Institute of Human Virology, Nigeria, Nigeria

Teresia Otieno
ATHENA Network, United States

George Victor Owino
International AIDS Vaccine Initiative (IAVI), Kenya

Gbemisola Oyeneyin
Initiative for Better Public Health, Nigeria

Thesla Palanee-Phillips
Wits Reproductive Health and HIV Institute, South Africa

Mickey Patel
Geisel School of Medicine at Dartmouth, United States

San Patten
San Patten and Associates, Inc., Canada

Catia Perciani
University of Toronto, Canada

Capucine Phelip
Institut de Biologie et Chimie des Protéines, LBTI, UMR 5305 CNRS/Université de Lyon, France

Cyril Planchais
INSERM U955, Team 16, VRI, France

Matthew Quaife
London School of Hygiene & Tropical Medicine, United Kingdom

Cecilia Rademeyer
University of Cape Town, South Africa

Hannah Rafferty
University of Oxford, United Kingdom
Srinika Ranasinghe  
Ragon Institute of MGH, MIT and Harvard, United States

Krishnaveni Reddy  
Wits Reproductive Health and HIV Institute, South Africa

Galit Regev  
University of Pittsburgh, United States

Yanqin Ren  
Fudan University, China

Catherine Riou  
University of Cape Town, South Africa

Marta Rodriguez-Garcia  
Geisel School of Medicine at Dartmouth, United States

Miriam Rosas  
AIDS Research Institute, IrsiCaixa, Spain

Arangassery Rosemary Bastian  
Northwestern University, United States

Claire Ruberman  
Johns Hopkins University, United States

Sweety Samal  
Translational Health Science and Technology Institute (THSTI), India

Anne Schley  
AVAC, South Africa

Jeffrey Schneider  
Northwestern University, United States

Kevin Selva  
Peter Doherty Institute for Infection and Immunity, University of Melbourne, Australia

Liang Shang  
University of Minnesota, United States

Monisha Sharma  
University of Washington, United States

Tripti Shrivastava  
Translational Health Science and Technology Institute (THSTI), India

Jiayi Shu  
Institut Pasteur of Shanghai, China

Paola Silveira  
Federal University of Rio de Janeiro, Brazil

Aida Sivro  
Centre for the AIDS Programme of Research in South Africa (CAPRISA), South Africa

Stacey Abigail Smith  
Emory University, United States

Livingstone Ssali  
The AIDS Support Organisation (TASO), Uganda

James Steinhardt  
Institute for Bioscience and Biotechnology Research, United States

Karunsinee Suphaphiphat  
Commissariat à L’énergie Atomique et aux Énergies Alternatives (CEA), France

Kazuki Tanaka  
Matsushita Project Laboratory, Center for AIDS Research, Kumamoto University, Japan
Jeffrey Teigler  
U.S. Military HIV Research Program, Henry M. Jackson Foundation for the Advancement of Military Medicine, United States

William Tolbert  
University of Maryland, United States

Aime Marcel Tongo Passo  
Division of Computational Biology and Institute of Infectious Diseases and Molecular Medicine, University of Cape Town, South Africa

Damien Tully  
Ragon Institute of MGH, MIT and Harvard, United States

Morenike Ukpong  
Institute of Public Health/New HIV Vaccine and Microbicide Advocacy Society, Nigeria

Gisele Umviligihozo  
Projet San Francisco (PSF), Rwanda

Michiel van Diepen  
University of Cape Town, South Africa

Matthew Vaughan  
Asia Pacific Coalition on Male Sexual Health, Thailand

Thomas Vazquez  
I3 Laboratory–INSERM U959–GHPS Paris, France

Mathias Wambuzi  
Uganda Virus Research Institute (UVRI)–International AIDS Vaccine Initiative (IAVI), Uganda

Chu Wang  
National Engineering Laboratory for AIDS Vaccine, School of Life Sciences, Jilin University, China

Yimeng Wang  
Institute for Bioscience and Biotechnology Research, University of Maryland, United States

Nicole Welsh  
Queen’s University Belfast, United Kingdom

Jocelyn Wessels  
McMaster University, Canada

Constantinos Kurt Wibmer  
Centre for HIV and STIs, National Institute for Communicable Diseases and University of the Witwatersrand, South Africa

Terri Wilder  
Mount Sinai Institute for Advanced Medicine, United States

Xilin Wu  
University of Hong Kong, Hong Kong

Irene Xie  
University of Manitoba, Canada

Ntando Yola  
Desmond Tutu HIV Foundation, South Africa

Wildeman Zapata  
University of Antioquia, Colombia

Jason Zucker  
Columbia University Medical Center, United States

Margaret Zulu  
Southern African AIDS Trust, South Africa